Use of Colchicine for Pericardial Inflammation: Risks and Toxicities-A Cautionary Tale

Ofer Perzon; Ariel Kenig; Yakov Fellig; Dror Mevorach

doi:10.1016/j.jaccas.2022.08.027

Use of Colchicine for Pericardial Inflammation: Risks and Toxicities-A Cautionary Tale

JACC Case Rep. 2022 Nov 2;4(21):1449-1452. doi: 10.1016/j.jaccas.2022.08.027.

Authors

Ofer Perzon^{1

2}, Ariel Kenig^{1

2}, Yakov Fellig^{2

3}, Dror Mevorach^{2

4}

Affiliations

¹ Department of Internal Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
² Faculty of Medicine, Hebrew University, Jerusalem, Israel.
³ Department of Pathology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
⁴ Institute of Rheumatology-Immunology-Allergology and the Wohl Institute for Translational Medicine, Department of Medicine, Hadassah Medical Center, Jerusalem, Israel.

Abstract

Colchicine is commonly used as part of the treatment of acute and recurrent pericarditis. Neuromyopathy is a well-known, but probably underreported, side effect of colchicine. Here we present a unique case of a 56-year-old woman with recurrent episodes of colchicine-induced neuromyopathy over many years. (Level of Difficulty: Beginner.).

Keywords: CPK, creatinine phosphokinase; EMG, electromyography; GBS, Guillain-Barré syndrome; colchicine; neuromyopathy; pericarditis; vacuolar myopathy.

Publication types

Case Reports